Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Phillip Cowley & Julia Adam. (2002) Recent advances in the cannabinoids. Expert Opinion on Therapeutic Patents 12:10, pages 1475-1489.
Read now
Read now
Articles from other publishers (19)
Thomas Murphy, Justin Matheson, Robert E. Mann, Bruna Brands, Christine M. Wickens, Arun K. Tiwari, Clement C. Zai, James Kennedy & Bernard Le Foll. (2021) Influence of Cannabinoid Receptor 1 Genetic Variants on the Subjective Effects of Smoked Cannabis. International Journal of Molecular Sciences 22:14, pages 7388.
Crossref
Crossref
Thomas Murphy & Bernard Le Foll. (2020) Targeting the Endocannabinoid CB1 Receptor to Treat Body Weight Disorders: A Preclinical and Clinical Review of the Therapeutic Potential of Past and Present CB1 Drugs. Biomolecules 10:6, pages 855.
Crossref
Crossref
M. ZUBRZYCKIM. STASIOLEK & M. ZUBRZYCKA. (2019) Opioid and Endocannabinoid System in Orofacial Pain. Physiological Research, pages 705-715.
Crossref
Crossref
Jose M. Trigo & Bernard Le Foll. (2015) Inhibition of monoacylglycerol lipase (MAGL) enhances cue-induced reinstatement of nicotine-seeking behavior in mice. Psychopharmacology 233:10, pages 1815-1822.
Crossref
Crossref
Maria Grazia Cascio & Pietro Marini. 2015. Endocannabinoids. Endocannabinoids
39
58
.
Bernard Le Foll, Abhiram Pushparaj, Yaroslaw Pryslawsky, Benoit Forget, Kiran Vemuri, Alexandros Makriyannis & Jose M. Trigo. (2014) Translational strategies for therapeutic development in nicotine addiction: Rethinking the conventional bench to bedside approach. Progress in Neuro-Psychopharmacology and Biological Psychiatry 52, pages 86-93.
Crossref
Crossref
Leire Reguero, Nagore Puente, Izaskun Elezgarai, Almudena Ramos-Uriarte, Inmaculada Gerrikagoitia, José-Luis Bueno-López, Francisco Doñate & Pedro Grandes. (2013) Subcellular localization of NAPE-PLD and DAGL-α in the ventromedial nucleus of the hypothalamus by a preembedding immunogold method. Histochemistry and Cell Biology 141:5, pages 543-550.
Crossref
Crossref
Jakub Fichna, JodiAnne T. Wood, Malvina Papanastasiou, Subramanian K. Vadivel, Piotr Oprocha, Maciej Sałaga, Marta Sobczak, Anna Mokrowiecka, Adam I. Cygankiewicz, Piotr K. Zakrzewski, Ewa Małecka-Panas, Wanda M. Krajewska, Piotr Kościelniak, Alexandros Makriyannis & Martin A. Storr. (2013) Endocannabinoid and Cannabinoid-Like Fatty Acid Amide Levels Correlate with Pain-Related Symptoms in Patients with IBS-D and IBS-C: A Pilot Study. PLoS ONE 8:12, pages e85073.
Crossref
Crossref
B. Palouzier-Paulignan, M.-C. Lacroix, P. Aime, C. Baly, M. Caillol, P. Congar, A. K. Julliard, K. Tucker & D. A. Fadool. (2012) Olfaction Under Metabolic Influences. Chemical Senses 37:9, pages 769-797.
Crossref
Crossref
Islam Gamaleddin, Mihail Guranda, Steven R Goldberg & Bernard Le Foll. (2011) The selective anandamide transport inhibitor VDM11 attenuates reinstatement of nicotine seeking behaviour, but does not affect nicotine intake. British Journal of Pharmacology 164:6, pages 1652-1660.
Crossref
Crossref
Carol Addy, Paul Rothenberg, Susie Li, Anup Majumdar, Nancy Agrawal, Hankun Li, Ling Zhong, Jinyu Yuan, Andrea Maes, Stephanie Dunbar, Josee Cote, Kim Rosko, Kristien Van Dyck, Inge De Lepeleire, Jan de Hoon, Anne Van Hecken, Marleen Depré, Annemie Knops, Keith Gottesdiener, Aubrey Stoch & John Wagner. (2008) Multiple-Dose Pharmacokinetics, Pharmacodynamics, and Safety of Taranabant, a Novel Selective Cannabinoid-1 Receptor Inverse Agonist, in Healthy Male Volunteers. The Journal of Clinical Pharmacology 48:6, pages 734-744.
Crossref
Crossref
Michael Soyka, Gabriele Koller, Peggy Schmidt, Otto-Michael Lesch, Markus Leweke, Christoph Fehr, Horst Gann & Karl F. Mann. (2008) Cannabinoid Receptor 1 Blocker Rimonabant (SR 141716) for Treatment of Alcohol Dependence. Journal of Clinical Psychopharmacology 28:3, pages 317-324.
Crossref
Crossref
Carol Addy, Susie Li, Nancy Agrawal, Julie Stone, Anup Majumdar, Ling Zhong, Hankun Li, Jinyu Yuan, Andrea Maes, Paul Rothenberg, Josee Cote, Kim Rosko, Corinne Cummings, Steven Warrington, Malcolm Boyce, Keith Gottesdiener, Aubrey Stoch & John Wagner. (2008) Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Taranabant, a Novel Selective Cannabinoid-1 Receptor Inverse Agonist, for the Treatment of Obesity: Results From a Double-Blind, Placebo-Controlled, Single Oral Dose Study in Health. The Journal of Clinical Pharmacology 48:4, pages 418-427.
Crossref
Crossref
Luciano De Petrocellis & Vincenzo Di Marzo. 2005. Endocannabinoids. Endocannabinoids.
Gabriele Murineddu, Stefania Ruiu, Jean-Mario Mussinu, Giovanni Loriga, Giuseppe E. Grella, Mauro A.M. Carai, Paolo Lazzari, Luca Pani & Gérard A. Pinna. (2005) Tricyclic pyrazoles. Part 2: Synthesis and biological evaluation of novel 4,5-dihydro-1H-benzo[g]indazole-based ligands for cannabinoid receptors. Bioorganic & Medicinal Chemistry 13:9, pages 3309-3320.
Crossref
Crossref
Alessia Ligresti, Tiziana Bisogno, Isabel Matias, Luciano De Petrocellis, Maria Grazia Cascio, Vittorio Cosenza, Giuseppe D’argenio, Giuseppe Scaglione, Maurizio Bifulco, Italo Sorrentini & Vincenzo Di Marzo. (2003) Possible endocannabinoid control of colorectal cancer growth. Gastroenterology 125:3, pages 677-687.
Crossref
Crossref
Vincenzo Di Marzo. (2003) Manipulation of the endocannabinoid system by a general anaesthetic. British Journal of Pharmacology 139:5, pages 885-886.
Crossref
Crossref
Luciano De Petrocellis, Tiziana Bisogno & Vincenzo Di Marzo. 2003. Advances in Modelling and Clinical Application of Intravenous Anaesthesia. Advances in Modelling and Clinical Application of Intravenous Anaesthesia
215
225
.
V. Di Marzo, L. De Petrocellis, F. Fezza, A. Ligresti & T. Bisogno. (2002) Anandamide receptors. Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA) 66:2-3, pages 377-391.
Crossref
Crossref